Siddhartha Yadav

Assistant Professor

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Science Medical Science professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Siddhartha Yadav is an Assistant Professor at Mayo Clinic, USA. His research focuses on the genomic and immune landscape of pancreatic ductal adenocarcinoma, as well as germline testing and cancer risk associated with BRCA1, BRCA2, and other pathogenic variants. He has contributed to multiple studies exploring survival outcomes in breast cancer and has developed innovative risk prediction models integrating genetic and epidemiologic factors.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES

View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES

View details

Diana M Eccles

University of Southampton

UNITED KINGDOM

View details

Catherine Marshall

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

Joanne Kotsopoulos

CANADA

View details

Stig E. Bojesen

Copenhagen University Hospital

DENMARK

View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES

View details

Eric Polley

Associate Professor

University of Chicago

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Siddhartha Yadav

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2

Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality

Development of a breast cancer risk prediction model integrating monogenic, polygenic, and epidemiologic risk

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline

Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat

Preparing Hematology/Oncology Fellows for Success: Implementing an Annual Career Development and Research Retreat

Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry

Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast

Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast

Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study

iBreastExam: Time for Formal Operation in Nepal

Collecting duct carcinoma: A single‐institution retrospective study

Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast

Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer

A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer

Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years

Collaborators (8)

Song Yao

FEI CHEN

Diana M Eccles

Catherine Marshall

Joanne Kotsopoulos

Stig E. Bojesen

Jeffrey Weitzel

Eric Polley

Make your next move.